Physicians underestimate the frequency of generic carbamazepine substitution: Results of a survey and review of the problem

Epilepsy and Behavior

Volumn 3, Issue 6 I, 2002, Pages 522-525

  Wilner, Andrew N ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GENERIC DRUG;

AWARENESS; CLINICAL PRACTICE; COMPUTER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG QUALITY; DRUG SAFETY; DRUG UTILIZATION; EPILEPSY; HUMAN; MEDICAL AUDIT; MEDICAL SOCIETY; MULTIPLE CHOICE TEST; NEUROLOGIC DISEASE; PHYSICIAN ATTITUDE; PRESCRIPTION; QUESTIONNAIRE; RASH; REVIEW; SUSPENSION; UNITED STATES; UTILIZATION REVIEW;

EID: 0041383894     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-5050(02)00527-9     Document Type: Article

References (18)

1. Lesser RP, Krauss G. Buy some today. Can generics be safely substituted for brand-name drugs? Neurology 2001;57:571-3.
2. Wilder BJ, Leppik I, Hietpas TJ, Cloyd JC, Randinitis EJ, Cook J. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology 2001;57:582 -9.
3. Nuwer MR, Browne TR, Dodson WE, et al. Generic substitutions for antiepileptic drugs. Neurology 1990;40:1647-51.
4. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Neurology 1990;40:1641-3.
5. IMS NPA Plus audit year to date October 2001.
6. Ohio Revised Code Ann. 4729.38.
7. Texas Occupations Code 562.008.
8. Pennsylvania statutes, 35 P.S. 960.3.
9. http://fda.gov/cder/ogd/index.htm. FDA Center for Drug Evaluation and Research.
10. Approved drug products with therapeutic equivalence evaluations (the Orange Book), 21st ed. Washington, DC: US Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Information Technology, Division of Data Management and Services.
11. Switching to generic medications linked to renewed seizure activity. N Y J Epilepsy 1986;V(1).
12. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993;43:2696-7.
13. Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992;42:1147-53.
14. Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, Forsythe WI. Breakthrough seizures with generic carbamazepine: a consequence of poorer availability? Br J Clin Pract 1990;11:270-3.
15. Jumao-as A, Bella I, Craig B, Lowe J, Dasheiff RM. Comparison of steady-state blood levels of two carbamazepine formulations. Epilepsia 1989;30:67-70.
16. Olling M, Mensinga TT, Barends DM, Groen C, Lake OA, Meulenbelt J. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 1999;20:19-28.
17. Sachdeo RC, Belendiuk G. Generic versus branded carbamazepine. Lancet 1987 Jun 20:1432 [letter].
18. Busch RL. Generic carbamazepine and erythema multiforme: generic-drug nonequivalency. N Engl J Med 321:692-3 [letter].